AERIE PHARMACEUTICALS INC
AERI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AERI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2022.
Tracking 5 pipeline candidates · 3 clinical trials for AERIE PHARMACEUTICALS INC.
Run AERIE PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AERIE PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
54.1 months
OCF -$11M · Net income -$27M
Lead: Approved
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is AERIE PHARMACEUTICALS INC's lead drug candidate?
AERIE PHARMACEUTICALS INC's most advanced tracked candidate is ar-1105 (Phase 2) for macular edema due to retinal vein occlusion ("RVO").
Who is the CEO of AERIE PHARMACEUTICALS INC?
Emperor Boulevard is the chief executive officer of AERIE PHARMACEUTICALS INC (AERI).
What therapeutic areas does AERIE PHARMACEUTICALS INC focus on?
AERIE PHARMACEUTICALS INC develops therapies across Ophthalmology, Cardiovascular, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.